Aspiryna może zapobiegać powikłaniom COVID-19? Badanie pilotażowe

Jonathan H. Chow i wsp. Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019. Anesth Analg 2021;132:930–41

In summary, our analysis suggests that aspirin use may have beneficial effects in patients with COVID-19. Mechanistically, these findings are plausible given aspirin’s irreversible antiplatelet effect and the frequent hypercoagulability observed in COVID-19 patients.

The results of our study are intriguing, especially because aspirin has been thoroughly studied in chronic cardiovascular disease, has a well-described safety profile, and is readily available throughout the world.

The preliminary, hypothesis-generating nature of our study provides the basis for a larger study, which will be needed to confirm our findings and assess the extent to which the relationships observed in our study are causal.

Until a randomized controlled trial of aspirin is performed, it is imperative to exercise cautious optimism and deliberately balance aspirin’s known risks against its potential benefits in patients afflicted by COVID-19.

Anesthesia & Analgesia, kwiecień 2021

0 replies on “Aspiryna może zapobiegać powikłaniom COVID-19? Badanie pilotażowe”